Advanced in Chronic B-Cell Leukemia (CBCL)

Muhit Ozcan

Ankara, TR 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Chronic B-Cell Leukemia (CBCL)
Ankara, TR 
OverviewLocationsClinical Research

Overview

Muhit Ozcan practices in Ankara, Turkey. Ozcan is rated as an Advanced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Their top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Splenectomy.

Their clinical research consists of co-authoring 73 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Chronic B-Cell Leukemia (CBCL).

Locations

Ankara, Turkey
Other Locations
Dikimevi, 06590, Turkey
Cebeci, 06590, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib
A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib
Enrollment Status: Recruiting
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drug: Radotinib HCl
Study Phase: Phase 3

73 Total Publications

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.
Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ozcan's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile